Arbor, Vol 191, No 773 (2015)

El cáncer ginecológico


https://doi.org/10.3989/arbor.2015.773n3007

Antonio González-Martín
MD Anderson Cancer Center, España

Resumen


El cáncer ginecológico es un problema de salud en Europa de primer orden en la medida en que en su conjunto, e incluyendo específicamente el cáncer de ovario, de útero y de cuello uterino, representa la tercera causa de cáncer en la mujer en Europa, por detrás del cáncer de mama y el cáncer colorrectal, y la tercera causa de muerte por cáncer tras el cáncer de mama y cáncer de pulmón. La mejora en estas cifras pasa por la implementación de las medidas preventivas disponibles, especialmente en cáncer de cuello uterino, el diagnóstico precoz cuando es posible, la aplicación de la mejor terapéutica por equipos multidisciplinares especializados, y el conocimiento de las alteraciones moleculares de estas enfermedades, como base para el desarrollo de terapias personalizadas y eficientes.

Palabras clave


cáncer de cuello uterino; cáncer de ovario; cáncer de útero

Texto completo:


HTML PDF XML

Referencias


Aalders, J., Abeler, V., Kolstad, P. y Onsrud, M. (1980). Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics & Gynecolgy, 56, 4, pp. 419-427.

Armstrong, D., Bunden, B. y Wenel, L. (2006). Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. New England Journal of Medicine, 354, pp. 34-43. http://dx.doi.org/10.1056/NEJMoa052985

Ashworth, A. (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology, 26, 22, pp. 3785-3790. http://dx.doi.org/10.1200/JCO.2008.16.0812

Bast, R. C., Jr., Hennessy, B. y Mills, G. B. (2009). The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 9, 6, pp. 415-428. http://dx.doi.org/10.1038/nrc2644

Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D. Dao, F., Dhir, R., DiSaia, P., Gabra, H. et al. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 7353, pp. 609-615. http://dx.doi.org/10.1038/nature10166

Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 26, pp. 2473-2483. http://dx.doi.org/10.1056/NEJMoa1104390

Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B. et al. (2014a). Endometrial cancer: a review and current management strategies: part II. Gynecologic Oncology, 134, 2, pp. 393-402.

Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B. et al. (2014b). Endometrial cancer: a review and current management strategies: part I. Gynecologic Oncology, 134, 2, pp. 385-392.

Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C. et al. (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 355, 9213, pp. 1404-1411. http://dx.doi.org/10.1016/s0140-6736(00)02139-5

du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I. y Pfisterer, J. (2009a). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115, 6, pp. 1234-1244.

du Bois, A., Rochon, J., Pfisterer, J. y Hoskins, W. J. (2009b). Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecologic Oncology, 112, 2, pp. 422-436.

Gonzalez-Martin, A., Bover, I., Del Campo, J. M., Redondo, A. y Vidal, L. (2014). SEOM guideline in ovarian cancer 2014. Clinical and Translational Oncology, 16, 12, pp. 1067-1071. http://dx.doi.org/10.1007/s12094-014-1229-z

Hogberg, T., Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A. A., Sorbe, B. et al. (2010). Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. European Journal of Cancer, 46, 13, pp. 2422-2431. http://dx.doi.org/10.1016/j.ejca.2010.06.002

Katsumata, N., Yasuda, M., Isonishi, S., Michimae, H., Kimura, E., Aoki, D. et al. (2012). Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. ASCO Meeting Abstracts, 30, abstract 5003.

Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D. et al. (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 92, 3, pp. 744-751. http://dx.doi.org/10.1016/j.ygyno.2003.11.048

Kitchener, H., Swart, A. M., Qian, Q., Amos, C. y Parmar, M. K. (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 373, 9658, pp. 125-136.

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G. et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366, 15, pp. 1382-1392. http://dx.doi.org/10.1056/NEJMoa1105535

McGraw, S. L. y Ferrante, J. M. (2014). Update on prevention and screening of cervical cancer. World Journal of Clinical Oncology, 5, 4, pp. 744-752. http://dx.doi.org/10.5306/wjco.v5.i4.744

Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. et al. (2010). Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet, 375, 9717, pp. 816-823. http://dx.doi.org/10.1016/S0140-6736(09)62163-2

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 26, pp. 2484-2496. http://dx.doi.org/10.1056/NEJMoa1103799

Shih, K. K., Yun, E., Gardner, G. J., Barakat, R. R., Chi, D. S. y Leitao, M. M., Jr. (2011). Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecologic Oncology, 122, 3, pp. 608-611. http://dx.doi.org/10.1016/j.ygyno.2011.05.020

Stuart, G. C., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J. et al. (2011). 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer, 21, 4, pp. 750-755. http://dx.doi.org/10.1097/IGC.0b013e31821b2568

Susumu, N., Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S. et al. (2008). Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology, 108, 1, pp. 226-233. http://dx.doi.org/10.1016/j.ygyno.2007.09.029

Tewari, K. S. y Monk, B. J. (2014). New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clinical Cancer Research, 20, 21, pp. 5349-5358. http://dx.doi.org/10.1158/1078-0432.CCR-14-1099

Tewari, K. S., Sill, M. W., Long, H. J., 3rd, Penson, R. T., Huang, H., Ramondetta, L. M. et al. (2014). Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine, 370, 8, pp. 734-743. http://dx.doi.org/10.1056/NEJMoa1309748

Wright, J. D., Barrena Medel, N. I., Sehouli, J., Fujiwara, K. y Herzog, T. J. (2012). Contemporary management of endometrial cancer. Lancet, 379, 9823, pp. 1352-1360. http://dx.doi.org/10.1016/S0140-6736(12)60442-5




Copyright (c) 2015 Consejo Superior de Investigaciones Científicas (CSIC)

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento 4.0 Internacional.


Contacte con la revista arbor@csic.es

Soporte técnico soporte.tecnico.revistas@csic.es